1. Triggering Toll-Like Receptor 5 Signaling During Pneumococcal Superinfection Prevents the Selection of Antibiotic Resistance.
- Author
-
Costa C, Sirard JC, Gibson PS, Veening JW, Gjini E, and Baldry M
- Subjects
- Amoxicillin pharmacology, Amoxicillin administration & dosage, Drug Resistance, Bacterial, Humans, Animals, Models, Theoretical, Superinfection microbiology, Superinfection drug therapy, Streptococcus pneumoniae drug effects, Toll-Like Receptor 5 metabolism, Toll-Like Receptor 5 agonists, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Signal Transduction drug effects, Flagellin, Pneumococcal Infections drug therapy, Pneumococcal Infections microbiology, Pneumococcal Infections immunology, Pneumococcal Infections prevention & control
- Abstract
Toll-like receptor 5 (TLR5) signaling plays a key role in antibacterial defenses. We previously showed that respiratory administration of flagellin, a potent TLR5 agonist, in combination with amoxicillin (AMX) improves the treatment of primary pneumonia or superinfection caused by AMX-sensitive or AMX-resistant Streptococcus pneumoniae. Here, the impact of adjunct flagellin therapy on antibiotic dose/regimen and the selection of antibiotic-resistant S. pneumoniae was investigated using superinfection with isogenic antibiotic-sensitive and antibiotic-resistant bacteria and population dynamics analysis. Our findings demonstrate that flagellin allows for a 200-fold reduction in the antibiotic dose, achieving the same therapeutic effect observed with antibiotic alone. Adjunct treatment also reduced the selection of antibiotic-resistant bacteria in contrast to the antibiotic monotherapy. A mathematical model was developed that captured the population dynamics and estimated a 20-fold enhancement immune-modulatory factor on bacterial clearance. This work paves the way for the development of host-directed therapy and refinement of treatment by modeling., Competing Interests: Potential conflicts of interest. J. C. S. is the inventor of the patents WO2009156405, WO2011161491, and WO2015011254, which describes the use of the recombinant flagellin in this study as an adjunct of antibiotics. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2024
- Full Text
- View/download PDF